KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Invested Capital (2017 - 2025)

Historic Invested Capital for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $2.5 billion.

  • Amneal Pharmaceuticals' Invested Capital rose 708.54% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 708.54%. This contributed to the annual value of $2.3 billion for FY2024, which is 670.65% down from last year.
  • Amneal Pharmaceuticals' Invested Capital amounted to $2.5 billion in Q3 2025, which was up 708.54% from $2.1 billion recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Invested Capital peaked at $3.1 billion during Q4 2021, and registered a low of $403.7 million during Q1 2021.
  • Its 5-year average for Invested Capital is $2.1 billion, with a median of $2.3 billion in 2024.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Invested Capital tumbled by 8656.62% in 2021 and then surged by 57228.74% in 2022.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Invested Capital stood at $3.1 billion in 2021, then dropped by 8.83% to $2.8 billion in 2022, then decreased by 13.04% to $2.4 billion in 2023, then fell by 6.71% to $2.3 billion in 2024, then grew by 8.23% to $2.5 billion in 2025.
  • Its Invested Capital was $2.5 billion in Q3 2025, compared to $2.1 billion in Q2 2025 and $2.1 billion in Q1 2025.